Sun Pharma’s $11.75bn Organon deal targets 2027 close

Deal announcement and headline terms

Sun Pharmaceutical Industries said it has signed a definitive agreement to acquire Organon & Co in an all-cash transaction. The deal values Organon at an enterprise value of about $11.75 billion, including debt, making it one of India’s biggest outbound acquisitions. Under the agreement, Sun Pharma will buy all outstanding Organon shares for $14.00 per share in cash. The companies said the offer price represents a premium of more than 24% to Organon’s last close on Friday. Organon is a U.S. drugmaker that was spun off from Merck in 2021.

What Sun Pharma is buying in Organon

Organon focuses on women’s health, biosimilars, and established medicines, according to the deal announcement. Sun Pharma said the acquisition is aligned with its strategy of growing its Innovative Medicines business. The company also highlighted Organon’s portfolio and global footprint as key parts of the rationale. Sun Pharma said Organon’s stakeholder relationships would complement Sun Pharma’s existing strengths. The transaction would give Sun Pharma full ownership of Organon.

Strategic rationale: innovation, biosimilars, women’s health

Sun Pharma said it aims to grow its innovative medicines portfolio through the Organon acquisition. It also said the deal enables its entry into biosimilars as a top-10 global player. Another stated goal is to extend its push into women’s health, where Organon has a dedicated focus. In the companies’ communication, the combined entity is described as a stronger player in established brands and branded generics. Sun Pharma also disclosed that its high-growth Global Innovative Medicines portfolio spans dermatology, ophthalmology, and oncodermatology, and accounts for about 20% of company sales.

Funding plan and transaction structure

Sun Pharma said it plans to fund the acquisition using a combination of available cash resources and committed financing from banks. The transaction is expected to be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. The companies said the deal is expected to close in early 2027. Closing is subject to customary conditions, including regulatory approvals and Organon stockholder approval.

Financial markers disclosed with the deal

In the deal material, Sun Pharma indicated the combined company would be a stronger cash-generating business. It added that EBITDA and cash flow are set to nearly double, supporting deleveraging from post-transaction net debt to EBITDA of 2.3x. Separately, a report citing a Sun Pharma exchange filing said the combined revenue would be $12.4 billion and that the innovative medicines revenue share would rise to 27%. The same report said Sun Pharma would inherit Organon’s debt of $1.6 billion.

How big is this for Sun Pharma and India Inc

Sun Pharma is India’s biggest pharmaceutical company and was described as having a market value of more than $10 billion. Another report put Sun Pharma’s market valuation at around ₹4.03 lakh crore (about $12.8 billion) at one point during the deal chatter, and around ₹3.9 lakh crore at current levels in that report. The Organon acquisition has been framed as one of the largest overseas acquisitions by an Indian company. A report also compared it with Tata Steel’s Corus acquisition for $12 billion in 2007.

Market reaction and investor concerns seen in deal chatter

Ahead of the definitive announcement, reports of a potential Organon acquisition affected Sun Pharma’s stock. One report said Sun Pharma shares fell 3.61% to a low of ₹1,619.05 on the BSE after the acquisition reports surfaced. The same report said the stock’s decline was about 5.4% so far in 2026 at that point. Analysts cited in the report flagged valuation and execution risks linked to a large outbound acquisition.

Competing bidders and the path to a binding agreement

One report said Sun Pharma was competing with Swedish private equity firm EQT and German pharmaceutical company Gruenthal in the race for Organon. It also said Sun Pharma submitted a binding offer of nearly $13 billion. The same report said Sun Pharma had evaluated Organon earlier and that the news flow around a possible final bid triggered a sharp move in Organon’s stock. Organon was described in that reporting as a debt-laden U.S. drugmaker focused on women’s health.

Key deal facts at a glance

Why the deal matters for the pharma sector

If completed, the acquisition would reshape Sun Pharma’s international profile by adding a larger platform in women’s health and biosimilars. The deal also reflects how large Indian drugmakers are using outbound M&A to add product portfolios and global reach rather than relying only on generics scale. The financing mix and the leverage metric disclosed with the transaction will be central for investors tracking balance-sheet impact after closing. Regulatory approvals and the Organon stockholder vote are the key procedural gates before the early-2027 closing timeline.

Conclusion

Sun Pharma’s agreement to buy Organon for $14 per share values the U.S. company at an enterprise value of about $11.75 billion and sets up a major overseas expansion move for India’s largest drugmaker. The companies have guided to an early-2027 closing, subject to regulatory and stockholder approvals. Until those clear, the market focus is likely to remain on financing, leverage, and execution milestones disclosed as the transaction progresses.